Using regadenoson for stress first-pass perfusion cardiac MR imaging: How, when, and why?

Area of Science:

• Cardiology
• Radiology
• Pharmacology

Background:

• Cardiac MRI is crucial for diagnosing coronary artery disease, assessing myocardial viability, and guiding revascularization decisions.
• Adenosine is the standard vasodilator for stress cardiac MRI, but its use can be limited by side effects and administration complexity.
• Regadenoson, an adenosine A2A receptor agonist, presents a promising alternative with favorable pharmacokinetic and safety profiles.

Purpose of the Study:

• To review the characteristics, safety, and application of regadenoson in stress cardiac MRI.
• To compare regadenoson with adenosine as a vasodilator for cardiac MRI.
• To discuss the clinical utility and reimbursement considerations for regadenoson in cardiac MRI.

Main Methods:

• Review of existing literature on regadenoson and cardiac MRI.
• Analysis of regadenoson's pharmacokinetic and pharmacodynamic properties.
• Discussion of clinical trial data and safety profiles.

Main Results:

• Regadenoson demonstrates rapid onset and offset of action, facilitating stress perfusion imaging.
• It has a favorable safety profile with fewer contraindications compared to adenosine.
• Regadenoson provides comparable diagnostic accuracy to adenosine for detecting significant coronary artery disease.

Conclusions:

• Regadenoson is a suitable and effective alternative to adenosine for vasodilator-induced stress cardiac MRI.
• Its ease of administration and safety profile enhance its utility in clinical practice.
• Further evaluation of its long-term prognostic value and broader reimbursement is warranted.